Thermo Fisher Scientific,Waltham,Mass,已纳入最终协议,以获得Mesa Biotech,私营的San Diego的分子诊断公司,大约4.5亿美元的现金。

Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech’s patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. The company is based in San Diego, California and has approximately 500 employees and revenues in 2020 of approximately $45 million.

Mesa Biotech's Accula Fur a / Flu B,RSV和Strep A测试已获得510(k)间隙和临床实验室改进修正案(CLIA)来自FDA的豁免。此外,Accula系统已从FDA接收到SARS-COV-2体外诊断测试的紧急使用授权(EUA),现在可用于患者护理环境,在30分钟内提供结果,精度高于其他快速测试的准确性在市场上。

“Mesa Biotech的创新平台将使我们能够在护理点加速可靠和准确的先进分子诊断的可用性。自热渔业公司执行副总裁兼首席运营官兼首席运营官Mark Stevenson表示,自大流行的迅速行动,为科学家和医疗专业人士提供支持,为COVID-19的前线提供支持,“Thermo Fisher Scientific副总裁兼首席运营官Mark Stevenson Mark Stevenson说。“The addition of Mesa Biotech’s easy-to-use, rapid PCR-based test is highly complementary to our existing offering and will further help us meet the continuing demand for covid-related testing while we work to rapidly scale and develop point-of care tests for other infectious diseases in the future.”

Mesa Biotech的总裁兼首席执行官Ingo Chakravarty说:“我非常自豪地为Mesa Biotech达到了迄今为​​止和兴奋的成为Thermo Fisher的前景。MESA的创新型PCR平台技术,将PCR精度与流动性和测试结果相结合,在30分钟内,在打击大流行的集体努力中已经发挥了有意义的作用。Thermo Fisher的规模,创新和全球范围将使我们能够更加显着放大我们技术在大流行期间对人类健康的影响,远远超过。“

该交易预计将于2021年第一季度完成,但须遵守惯常的结算条件,包括监管批准。完成后,业务将成为Thermo Fisher Life Solutions Seatments的一部分。

特色图片:Mesa Biotech Accula测试(Courtesy Mesa Biotech)